Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 in Previously Treated Mesothelioma
NCT01160458Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2010
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in mesothelioma, sponsored by National Cancer Institute. Started Jun 2010; status: completed.
02
Drugs
cixutumumab
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NCT01160458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160458.